CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial

W. He, M. Eriksson, E. Eliasson, F. Grassmann, M. Bäcklund, M. Gabrielson, M. Hammarström, S. Margolin, L. Thorén, Y. Wengström, S. Borgquist, P. Hall*, K. Czene

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial'. Together they form a unique fingerprint.

Medicine & Life Sciences